SM
ALNY icon

Sabby Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Sabby Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-941
Closed -$12M – 160
2017
Q4 		$12M Sell
941
-3,739
-80% -$470K 1.09% 19
2017
Q3 		$55M Buy
4,680
+2,966
+173% +$253K 3.59% 7
2017
Q2 		$13.7M Sell
1,714
-251
-13% -$16K 0.89% 17
2017
Q1 		$10.1M Buy
1,965
+725
+58% +$33.5K 0.54% 33
2016
Q4 		$4.64M Sell
1,240
-208
-14% -$8.71K 0.27% 54
2016
Q3 		$9.81M Buy
1,448
+461
+47% +$32.5K 0.37% 46
2016
Q2 		$5.48M Buy
+987
New +$62.2K 0.29% 52
2015
Q4 		– Sell
-1,676
Closed -$13.5M – 321
2015
Q3 		$13.5M Sell
1,676
-2,481
-60% -$276K 0.55% 30
2015
Q2 		$49.8M Buy
4,157
+908
+28% +$109K 1.82% 9
2015
Q1 		$33.9M Buy
3,249
+2,543
+360% +$258K 1.41% 16
2014
Q4 		$6.85K Sell
706
-1,649
-70% -$153K 0.22% 59
2014
Q3 		$18.4K Buy
2,355
+2,260
+2,379% +$146K 0.71% 26
2014
Q2 		$600K Buy
+95
New +$5.65K 0.03% 180
2013
Q3 		– Sell
-468
Closed -$1.45M – 198
2013
Q2 		$1.45M Buy
+468
New +$12.5K 0.1% 103

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Sabby Management's ALNY Position: Q2 2018 in Review

Sabby Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2018, closing a stake of 11,500 shares — an estimated $1.37M sold.

Sabby Management first reported a position in ALNY in Q2 2014 and held it in 5 quarters. The position peaked at $2.45M in Q4 2017. 310 funds tracked by Wall St. Rank hold ALNY as of Q2 2018.

  • Sabby Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Sabby Management sold 11,500 Alnylam Pharmaceuticals shares in Q2 2018, an estimated $1.37M.
  • Sabby Management first reported a position in Alnylam Pharmaceuticals in Q2 2014 and held it in 5 quarters.
  • Sabby Management's Alnylam Pharmaceuticals position peaked at $2.45M in Q4 2017.
  • 310 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2018.

Based on Sabby Management's 13F filing for Q2 2018, filed 14 Aug 2018.